19.050 +0.03 (0.16%)
After hours: 5:53PM EST
|Bid||18.900 x 1800|
|Ask||19.100 x 21500|
|Day's Range||18.94 - 19.29|
|52 Week Range||15.70 - 25.96|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.19|
The last few years for drug-maker Teva Pharmaceuticals (NASDAQ:TEVA) haven’t exactly been that wonderful. TEVA stock has plunged on a series of mishaps and issues. In fact, TEVA has fallen enough that America’s favorite value investor, Warren Buffett, has taken a huge interest in the stock over the last few quarters.
Israel-based Teva Pharmaceutical Industries said on Thursday it was moving its headquarters to Tel Aviv as part of a global restructuring. Teva, the world's largest generic drugmaker, said its new base will replace a number of sites located in the area of Petah Tikva, a city just outside of Tel Aviv -- Israel's commercial capital. Teva has been restructuring itself over the past year to deal with its massive debt, including lay-offs, site closings and the combining of divisions.
Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.
Headed into Tuesday’s session, stock charts of Micron Technology (NASDAQ:MU), Fortive (NYSE:FTV) and Morgan Stanley (NYSE:MS) are worth a closer look. Three weeks ago we pointed out how Micron Technology shares were trending lower, framed by a well-defined falling trading range. It may well be en route to the lower edge of that trading range again, but if it is, there’s a much bigger technical support line that will have to snap first.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry.
NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Several generic drug stocks were falling into the red on Monday, including Teva Pharmaceuticals, after Wall Street learned that a Washington Post report said an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry. Shares of Innovate Biopharmaceuticals were soaring despite any news from the company. Innovate Biopharmaceuticals, Inc.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing. The case now involves at least 16 companies and 300 drugs, the report said, citing Joseph Nielsen, an assistant attorney general and antitrust investigator in Connecticut, who has been a leader in the probe. Nielsen is quoted as saying, "this is most likely the largest cartel in the history of the United States." The victims were consumers and taxpayers, who have been carrying the high cost of overcharges on common antiboitics, blood-pressure medications, arthritis treatments, anxiety pills and more, said the report. Teva Pharmaceuticals Industries Ltd. ADRs fell 5.7% on the news. Mylan NV was down 4.6%, and Dr. Reddy Labs Ltd was down 3%. Abbott Labs was down 1.4% and Pfizer Inc. was down 1.6%. The S&P 500 was down 1.8% and the Dow Jones Industrial Average was down about 2%.
The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019.
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.
On December 5, Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, announced that the US FDA provided 510(K) clearance for its Ultra multifocal contact lenses for use in patients with astigmatism. The Ultra multifocal toric lens will be the first of its kind available for standard use.
Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.
How Is Teva Pharmaceutical Positioned in 2018? On November 29, Celltrion issued a press release announcing FDA approval of Truxima, a biosimilar version of Roche Holdings’ (RHHBY) Rituxan in three indications. On October 6, 2016, Teva Pharmaceutical (TEVA) issued a press release announcing a partnership with Celltrion for the commercialization of biosimilar versions of Rituxan and Herceptin in the US and Canada.
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.
U.S. Supreme Court justices on Tuesday grappled with a Swiss pharmaceutical company's effort to salvage a patent behind its lucrative anti-nausea drug in a case that could make it easier to cancel key patents, especially among smaller drugmakers. The justices asked tough questions of both sides during an hour of oral arguments in an appeal by Helsinn Healthcare S.A. of a lower court's decision to invalidate its patent on Aloxi, which paved the way for Israel-based Teva Pharmaceutical Industries to launch a generic version of the drug in March. Aloxi is used to prevent nausea and vomiting in patients receiving chemotherapy.
How Is Teva Pharmaceutical Positioned in 2018? On April 3, 2017, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Austedo for chorea associated with Huntington’s disease. According to Teva Pharmaceutical’s third-quarter earnings conference call, almost 40,000 people in the US suffer from Huntington’s disease.
How Is Teva Pharmaceutical Positioned in 2018? On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Ajovy, a humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy for migraine prevention indication. Teva Pharmaceutical expects to secure regulatory approval from the European Commission (or EC) for Ajovy in migraine prevention indication in H1 2019.
How Is Teva Pharmaceutical Positioned in 2018? On December 14, 2017, Teva Pharmaceutical (TEVA) issued a press release announcing a restructuring plan to reduce its cost base by $3.0 billion from $16.3 billion in fiscal 2017 to $13.3 billion in fiscal 2019. According to Teva Pharmaceutical’s third-quarter earnings conference call, since the beginning of the restructuring program, the company has already reduced its manpower by 9,100.
In its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) raised non-GAAP operating income guidance for fiscal 2018 from its projection in August 2018 of $4.3 billion–$4.6 billion to $4.6 billion–$4.8 billion. In February 2018, the company had projected its non-GAAP operating income for fiscal 2018 to fall in the range of $4.0 billion–$4.3 billion.
How Is Teva Pharmaceutical Positioned in 2018? During its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) raised the lower end of its revenue guidance for fiscal 2018 from its projection in August 2018 of $18.5 billion to $19.0 billion to $18.6 billion to $19.0 billion. In the third quarter, Teva Pharmaceutical reported total revenues of $4.53 billion, which is a YoY decline of 19.4%.
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.